These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

991 related articles for article (PubMed ID: 34512816)

  • 21. Development and validation of an immune prognostic classifier for clear cell renal cell carcinoma.
    Gu YY; Chen G; Lin P; Cheng JW; Huang ZG; Luo J; Zhai GQ; Wang YL; Yan HB; Li SH
    Cancer Biomark; 2020; 27(2):265-275. PubMed ID: 31929144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Novel Tumor Mutation Burden Related lncRNA Signature Identified Prognosis and Tumor Immune Microenvironment Features in Clear Cell Renal Cell Carcinoma.
    Lin L; Wu XH; Zhu JM; Chen SH; Chen YH; Lin F; Xue XY; Wei Y; Xu N; Zheng QS; Sun XL
    Comb Chem High Throughput Screen; 2023; 26(8):1503-1518. PubMed ID: 36165528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma.
    Xu WH; Xu Y; Tian X; Anwaier A; Liu WR; Wang J; Zhu WK; Cao DL; Wang HK; Shi GH; Qu YY; Zhang HL; Ye DW
    J Cell Mol Med; 2020 Aug; 24(16):9012-9027. PubMed ID: 32567187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and experimental validation of a tumor-infiltrating lymphocytes-related long noncoding RNA signature for prognosis of clear cell renal cell carcinoma.
    Deng Y; Guo K; Tang Z; Feng Y; Cai S; Ye J; Xi Y; Li J; Liu R; Cai C; Tan Z; Zhang Y; Han Z; Zeng G; Zhong W
    Front Immunol; 2022; 13():1046790. PubMed ID: 36505457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anoikis resistance regulates immune infiltration and drug sensitivity in clear-cell renal cell carcinoma: insights from multi omics, single cell analysis and
    Wen X; Hou J; Qi T; Cheng X; Liao G; Fang S; Xiao S; Qiu L; Wei W
    Front Immunol; 2024; 15():1427475. PubMed ID: 38953023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An immune-related lncRNA risk coefficient model to predict the outcomes in clear cell renal cell carcinoma.
    Tang C; Qu G; Xu Y; Yang G; Wang J; Xiang M
    Aging (Albany NY); 2021 Dec; 13(24):26046-26062. PubMed ID: 34954690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma.
    Gao J; Ye F; Han F; Jiang H; Zhang J
    Front Immunol; 2022; 13():956679. PubMed ID: 36177018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction of a ferroptosis-related signature based on seven lncRNAs for prognosis and immune landscape in clear cell renal cell carcinoma.
    Wei SY; Feng B; Bi M; Guo HY; Ning SW; Cui R
    BMC Med Genomics; 2022 Dec; 15(1):263. PubMed ID: 36528763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognosis of clear cell renal cell carcinoma (ccRCC) based on a six-lncRNA-based risk score: an investigation based on RNA-sequencing data.
    Zeng JH; Lu W; Liang L; Chen G; Lan HH; Liang XY; Zhu X
    J Transl Med; 2019 Aug; 17(1):281. PubMed ID: 31443717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel immune-related long non-coding RNA signature improves the prognosis prediction in the context of head and neck squamous cell carcinoma.
    Chen L; Cai Z; Lyu K; Cai Z; Lei W
    Bioengineered; 2021 Dec; 12(1):2311-2325. PubMed ID: 34167440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting the immune landscape of invasive breast carcinoma based on the novel signature of immune-related lncRNA.
    Shen S; Chen X; Hu X; Huo J; Luo L; Zhou X
    Cancer Med; 2021 Sep; 10(18):6561-6575. PubMed ID: 34378851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.
    Sun Z; Li T; Xiao C; Zou S; Zhang M; Zhang Q; Wang Z; Zhan H; Wang H
    World J Surg Oncol; 2022 Apr; 20(1):120. PubMed ID: 35422048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction of a 12-Gene Prognostic Risk Model and Tumor Immune Microenvironment Analysis Based on the Clear Cell Renal Cell Carcinoma Model.
    Wang S; Yu Z; Cao Y; Du P; Ma J; Ji Y; Yang X; Zhao Q; Hong B; Yang Y; Hai Y; Li J; Mao Y; Wu S
    Cancer Control; 2024; 31():10732748241272713. PubMed ID: 39115042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive analysis of necroptosis-related lncRNA signature with potential implications in tumor heterogeneity and prediction of prognosis in clear cell renal cell carcinoma.
    Lin H; Qu L; Chen G; Zhang C; Lu L; Chen Y
    Eur J Med Res; 2023 Jul; 28(1):236. PubMed ID: 37452355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive Analysis of N6-Methylandenosine-Related lncRNAs in Clear Cell Renal Cell Carcinoma: A Correlation With Prognosis, Tumor Progression, and Therapeutic Response.
    Meng C; Li J; Wang X; Ying Y; Li Z; Wang A; Li X
    Cancer Invest; 2024 Apr; 42(4):278-296. PubMed ID: 38644691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Expression and Prognostic Value of Co-stimulatory Molecules in Clear Cell Renal Cell Carcinoma (CcRcc).
    Wu C; Cai X; He C
    Comb Chem High Throughput Screen; 2024; 27(2):335-345. PubMed ID: 37171001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and validation of a ferroptosis-related lncRNA signature to robustly predict the prognosis, immune microenvironment, and immunotherapy efficiency in patients with clear cell renal cell carcinoma.
    Ju L; Shi Y; Liu G
    PeerJ; 2022; 10():e14506. PubMed ID: 36570012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upregulation of CCNB2 and a novel lncRNAs-related risk model predict prognosis in clear cell renal cell carcinoma.
    Ren C; Wang Q; Xu Z; Pan Y; Wang S; Liu X
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):64. PubMed ID: 38300330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of transforming growth factor beta induced (TGFBI) as an immune-related prognostic factor in clear cell renal cell carcinoma (ccRCC).
    Du GW; Yan X; Chen Z; Zhang RJ; Tuoheti K; Bai XJ; Wu HH; Liu TZ
    Aging (Albany NY); 2020 May; 12(9):8484-8505. PubMed ID: 32406866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Construction of a new immune-related lncRNA model and prediction of treatment and survival prognosis of human colon cancer.
    Liu S; Peng X; Wu X; Bu F; Yu Z; Zhu J; Luo C; Zhang W; Liu J; Huang J
    World J Surg Oncol; 2022 Mar; 20(1):71. PubMed ID: 35249533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.